Asia Pacific
Refine Search
Biotechnology
Japanese drugmaker Takeda has launched Fruzaqla (fruquintinib) in its home country. 22 November 2024
Biotechnology
Chinese biopharma CStone Pharmaceuticals has announced a strategic commercial collaboration with Pharmalink Store, a prominent pharmaceutical company based in the United Arab Emirates (UAE). 22 November 2024
Biotechnology
Zhongshan-based biopharma company Akeso will await the verdict of the Chinese medicines regulator on a penpulimab-based combo therapy. 22 November 2024
Pharmaceutical
Shanghai-based Zai Lab and New York’s Pfizer are to work together on the commercialization of Xacduro (sulbactam-durlobactam) in China. 22 November 2024
Biotechnology
Hong Kong-based Sino Biopharm has signed an equity investment and strategic collaboration agreement with LaNova Medicines, advancing its oncology focus. 22 November 2024
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Pharmaceutical
Ascentage Pharma will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme. 20 November 2024
Pharmaceutical
California, USA-based biotech Cytokinetics saw its shares fall as much as 4% to $9.67 yesterday, after it announced a deal with Germany’ Bayer. 20 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Biosimilars
Following US approval in May this year, South Korea’s Samsung Bioepis and US biotech Biogen have now won approval from the European Commission (EC) for their Opuviz 40mg/mL solution for injection in a vial, a biosimilar referencing Regeneron and Bayer’s Eylea (aflibercept). 18 November 2024
Biotechnology
Shanghai-based Junshi Biosciences has received UK regulatory approval for Loqtorzi (toripalimab) in nasopharyngeal carcinoma (NPC) and esophageal squamous cell carcinoma (ESCC). 18 November 2024
Biotechnology
Chinese biotech Keymed Biosciences has entered an exclusive licensing agreement with Platina Medicines for its bispecific antibody candidate, CM336. 18 November 2024
Pharmaceutical
In yet another sign of the mounting interest in radiopharmaceuticals, Tongrui Biopharma, a Chinese innovator in this area, has announced the completion of a $100 million series A+ financing round. 18 November 2024
Biotechnology
Shanghai-based biopharma Zai Lab has announced the pricing of its underwritten public offering at $25.50 per share, aiming to raise around $200 million. 15 November 2024
Biosimilars
South Korean biosimilars company Celltrion today announced its acquisition of iQone Healthcare Switzerland a specialty pharmaceutical company focused on distribution, sales, and marketing in Switzerland. 15 November 2024
Biotechnology
Merck & Co has entered into an exclusive global license to develop, manufacture and commercialize LM-299 from China-based clinical-stage biotech LaNova Medicines, bringing the US pharma giant into the newly attractive PD-1/VEGF bispecific antibody space. 15 November 2024
Biotechnology
Japanese drugmaker Nippon Shinyaku and USA-based Atsena Therapeutics have entered into an exclusive license agreement for the commercialization of ATSN-101 in the USA and Japan for advancing Atsena’s first- in-class, investigational gene therapy ATSN-101 for Leber congenital amaurosis caused by biallelic mutations in GUCY2D (LCA1). 13 November 2024
Pharmaceutical
Japanese drugmaker Maruho has entered into an exclusive license agreement to develop and commercialize Alchemedicine's aldehyde dehydrogenase 2 (ALDH2) activator following Maruho's exercise of the option right included in the exclusive negotiation and evaluation agreement that had already been executed between the companies. 4 July 2023
Pharmaceutical
China's National Medical Products Administration (NMPA) has recently launched a nationwide drug safety consolidation and enhancement campaign to establish a solid foundation for drug safety. 30 June 2023
Biotechnology
Chinese biotech Laekna has listed on the main board of Hong Kong’s stock exchange. 29 June 2023
Pharmaceutical
Adding to strong data released earlier this year form the SKYLIGHT 2 and SKYLIGHT 4 studies, Japanese drug major Astellas today announced positive top-line results from the Phase IIIb DAYLIGHT clinical trial for fezolinetant. 28 June 2023
Pharmaceutical
Japanese drugmaker Otsuka Pharmaceutical has announced positive results from a Phase III trial in its home country for brexpiprazole in the treatment of agitation associated with Alzheimer's dementia. 28 June 2023
Pharmaceutical
China’s National Medical Products Administration (NMPA) has approved Xigduo XR (dapagliflozin and metformin hydrochloride extended-release), a once-daily fixed-dose combination, for the treatment of adults with type-2 diabetes (T2D) as an adjunct to diet and exercise to improve glycemic control, from UK pharma major AstraZeneca. 27 June 2023
Biotechnology
Based on analysis of available information and input from a MEDACorp patent attorney, SVB Securities Research believes US pharma major AbbVie’s allegations that Brukinsa infringes on a recently granted patent (#11,672,803) are substantiative and could potentially result in damages to China-headquartered biotech BeiGene. 26 June 2023
Generics
Japanese pharma major Shionogi has signed seven sublicence agreements with the Medicines Patent Pool (MPP), a United Nations-backed international public health organization, for generic version of Shionogi's ensitrelvir fumaric acid, a COVID antiviral, to be manufactured by generics companies. 26 June 2023
Pharmaceutical
Japan’s largest drugmaker Takeda has released full results from the pivotal Phase III ADVANCE-CIDP 1 clinical trial investigating Hyqvia (immune globulin infusion 10% [human] with recombinant human hyaluronidase) as maintenance therapy in adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). 21 June 2023
Biotechnology
The World Health Organization (WHO) has granted WHO Emergency Use Listing (EUL) for the COVID-19 vaccine, SKYCovione, from South Korean company SK bioscience. 19 June 2023
Biotechnology
China-headquartered biotech BeiGene says it is aware that Pharmacyclics has filed a complaint against BeiGene and its US subsidiary alleging that its lead product Brukinsa (zanubrutinib) infringes a patent issued on June 13, 2023, to Pharmacyclics, a subsidiary of US pharma major AbbVie. 19 June 2023
Biotechnology
Sir Mene Pangalos, executive vice president, BioPharmaceuticals R&D, AstraZeneca, has stressed the importance of a new collaboration and licensing agreement to the company. 16 June 2023
Biotechnology
The European Medicines Agency (EMA) has validated and accepted for regulatory review the marketing authorization application (MAA) for fruquintinib. 16 June 2023
Biotechnology
Japanese drug major Astellas Pharma has entered a research collaboration and exclusive option agreement with privately held clinical-stage US biotech firm Cullgen to discover multiple innovative protein degraders. 15 June 2023
Biotechnology
Japanese drugmaker Chugai Pharmaceutical said today it has filed a regulatory application with the Ministry of Health, Labor and Welfare (MHLW) for the anti-C5 antibody crovalimab for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). 14 June 2023
Biotechnology
Soliris (eculizumab), from the AstraZeneca subsidiary Alexion, has won a new approval in China. 13 June 2023
Pharmaceutical
Spanish drugmaker PharmaMar and China-based Luye Pharma have revealed that the New Drug Application (NDA) submission of lurbinectedin has been accepted by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA). 12 June 2023
Biotechnology
A New Drug Application (NDA) was filed on June 9, 2023 with Japan's Ministry of Health, Labor and Welfare (MHLW) for zolbetuximab. 12 June 2023
Biotechnology
Having won accelerated approval in January this year, Alzheimer’s drug Leqembi (lecanemab) now looks set to get full approval from the US Food and Drug Administration (FDA) as early as next month. 10 June 2023
Biosimilars
South Korean contract development and manufacturing organization (CDMO) Samsung Biologics today revealed it has entered another strategic partnership with US pharma giant Pfizer (NYSE: PFE). 8 June 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze